Author at Microdose

Patrick McConnell

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Culture

2 Mar 2023

Building Models for Psychedelic Integration

Psychedelic integration....

By Patrick McConnell

Health & Wellness

16 Feb 2023

Adverse Ayahuasca Experiences Lead to Growth

Ayahuasca has a reputation for being a difficult ride....

By Patrick McConnell

Science

24 Jan 2023

The Microbiome and Psychedelics: It’s Not All in Your Head

The Microbiome and Psychedelics....

By Patrick McConnell

Culture

2 Dec 2022

A Deeper Look at Psychedelics Anonymous

Psychedelics Anonymous or “PA,” is a project of NFTs or non-fungible tokens, but also works to educate about psychedelics and make a real impact on addressing mental health....

By Patrick McConnell

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

17 Nov 2022

Predicting Psychedelic Outcomes

Can we better predict psychedelic outcomes? Imagine psychedelic settings curated to the individual, the right therapist, music, and even substance....

By Patrick McConnell

Science

1 Nov 2022

Decoding the Difference Between 5-MeO-DMT and N, N-DMT

While there are similarities between the two compounds, it’s important to understand that N, N-DMT and 5-MeO-DMT have significantly different effects and possible potential....

By Patrick McConnell

Law & Politics

25 Oct 2022

ATMA Journey Centers and Legal Psychedelics in Canada

The CEO of ATMA, David Harder, outlines a different path for psychedelics, one of government acceptance through cooperation with governmental bodies, training professionals, and clinical trials....

By Patrick McConnell

Industry, Science

20 Oct 2022

A Deeper Look at Ketamine and its Potential for Addiction

Ketamine might be the current poster child for psychedelic medicine, but mainstream media has been missing an important reality about ketamine's divergence and potential for addiction....

By Patrick McConnell

Law & Politics

17 Oct 2022

What Do Biden’s Cannabis Pardons Mean for Psychedelics?

The Biden administration's unconditional pardon announced on Oct 6 presents a much wider opportunity, which could also be a breakthrough in the long term for psychedelics....

By Patrick McConnell

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads